Baxter(US:BAX) Businesswireยท2025-10-17 00:05Core Viewpoint - Labaton Keller Sucharow LLP has filed a securities class action lawsuit against Baxter International, Inc. and certain executives, alleging misleading statements regarding the safety and efficacy of the Novum IQ Large Volume Pump, which has been linked to serious patient risks [1][2][4]. Company Overview - Baxter International, Inc. is a global healthcare company that develops and sells medical products for hospitals and healthcare facilities. The company recently launched the Novum IQ Large Volume Pump, which is intended for intravenous fluid delivery [2]. Allegations in the Lawsuit - The lawsuit claims that Baxter and its executives misled investors by failing to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion and overinfusion, posing serious risks to patients [2]. - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to the Novum LVP but did not adequately address these issues [2]. - The lawsuit also states that Baxter's communications regarding the safety, efficacy, and sales prospects of the Novum LVP were materially false and misleading [2]. Timeline of Events - Safety concerns regarding the Novum LVP emerged on April 7, 2025, following a whistleblower report about inaccurate infusion issues. Baxter issued warning letters to customers about potential risks shortly thereafter [3]. - On July 31, 2025, Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, leading to a 22.4% drop in the company's stock price [4]. Class Action Details - Individuals who purchased Baxter common stock during the specified class period may seek appointment as Lead Plaintiff in the lawsuit, with a deadline for filing motions set for December 15, 2025 [5].